Summary Objectives Multiple RCTs of interleukin-6 (IL-6) inhibitors in COVID-19 have been
published, with conflicting conclusions. We performed a meta-analysis to assess the impact …

Background Tocilizumab is a monoclonal antibody that interrupts interleukin-6 signalling,
reducing downstream effects on inflammation and the innate immune response. It was …

COVID-19 is a highly contagious respiratory disease, which mainly affects the lungs.
Critically ill patients are easily complicated by cytokine storms, acute respiratory distress …

Abstract The 2019 coronavirus disease (COVID‐19) pandemic has become a global crisis.
In the immunopathogenesis of COVID‐19, SARS‐CoV‐2 infection induces an excessive …

Background Elevated inflammatory cytokines in Coronavirus disease 2019 (COVID‐19)
affect the lungs leading to pneumonitis with a poor prognosis. Tocilizumab, a type of …

In this manuscript, we discuss the expectations versus the real-world results of four
repurposed COVID-19 drugs: tocilizumab, remdesivir, favipiravir, and dexamethasone from …

Bacterial infections may complicate the course of COVID-19 patients. The rate and
predictors of bacterial infections were examined in patients consecutively admitted with …

Purpose This executive summary of a national living guideline aims to provide rapid
evidence based recommendations on the role of drug interventions in the treatment of …

Objectives Cytokine release syndrome with elevated interleukin-6 (IL-6) levels is associated
with multiorgan damage and death in severe coronavirus disease 2019 (COVID-19). Our …

Abstract Introduction The Italian Society of Anti-Infective Therapy (SITA) and the Italian
Society of Pulmonology (SIP) constituted an expert panel for developing evidence-based …